netFormulary NHS
Buckinghamshire Formulary
Buckinghamshire Healthcare NHS Trust
Buckinghamshire CCG
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Notes:
1. Please refer to Appendix 11 of the BHT Medicines Policy for full details of policies and procedures for the prescribing, preparation and administration of chemotherapy (including intrathecal chemotherapy)

2. Use chemotherapy in accordance with NHSE National dose banding tables. For latest version see here.
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
08.01 Cytotoxic drugs (1,0)
Side-effects of cytotoxic drugs (0,1)
Drugs for cytotoxic-induced side-effects (5,4)
08.01.01 Alkylating drugs (14,2)
08.01.02 Anthracyclines and other cytotoxic antibiotics (11,0)
08.01.03 Antimetabolites (20,5)
08.01.04 Vinca alkaloids and etoposide (8,2)
08.01.05 Other antineoplastic drugs (42,5)
Amsacrine (1,0)
Arsenic trioxide (1,0)
Bevacizumab (1,1)
Bexarotene (0,1)
Bortezomib (1,0)
Brentuximab vedotin (1,0)
Cetuximab (1,0)
Crisantaspase (3,0)
Dacarbazine and Temozolomide (2,0)
Erlotinib (1,0)
Hydroxycarbamide (1,0)
Imatinab (0,0)
Ipilimumab (2,0)
Mitotane (0,1)
Panitumumab (1,0)
Pentostatin (1,0)
Platinum compounds (3,0)
Porfimer sodium and temoporfin (0,2)
Procarbazine (1,0)
Protein kinase inhibitors (25,4)
Taxanes (4,0)
Topoisomerase I inhibitors (3,1)
Trabectedin (1,1)
Trastuzumab (3,0)
Tretinoin (1,0)
Vismodegib (0,0)
08.02 Drugs affecting the immune response (0,0)
Immunosuppressant therapy (0,0)
08.02.01 Antiproliferative immunosuppressants (5,0)
08.02.02 Corticosteroids and other immunosuppressants (7,4)
08.02.03 Anti-lymphocyte monoclonal antibodies (9,0)
08.02.04 Other immunomodulating drugs (3,1)
Interferon Alfa (4,0)
Interferon beta (6,0)
Interferon gamma (0,0)
Aldesleukin (0,1)
BCG bladder instillation (1,0)
Canakinumab (0,0)
Dimethyl fumarate (1,0)
Fingolimod (1,0)
Glatiramer acetate (2,0)
Histamine (0,0)
Lenalidomide, pomalidomide, and thalidomide (3,0)
Mifamurtide (0,0)
Natalizumab (1,0)
Teriflunomide (1,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (1,1)
08.03.02 Progestogens (4,0)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (8,3)
08.03.04.02 Cancer: gonadorelin analogues and gonadotrophin-releasing hormone antagonists (1,0)
Gonadorelin analogues (1,0)
Anti-androgens (11,2)
Gonadotrophin-releasing hormone antagonists (0,0)
08.03.04.03 Somatostatin analogues (2,1)
netFormulary